Literature DB >> 14662733

Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.

C Thiemermann1.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors that are related to retinoid, steroid and thyroid hormone receptors. The PPAR subfamily comprises of three members, PPAR-alpha, PPAR-beta and PPAR-gamma. There is good evidence that ligands of PPAR-gamma, including certain thiazolinediones, reduce myocardial tissue injury and infarct size. The use of PPAR-gamma agonists in the treatment of heart failure is, however, controversial.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14662733      PMCID： PMC1574172          DOI： 10.1038/sj.bjp.0705586

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  20 in total

1.  Menarini Academy Cardiovascular Research Awards in Basic Science 2001: ligands of the orphan receptor peroxisome-proliferator activator-gamma reduce myocardial infarct size.

Authors:  C Thiemermann; N S Wayman
Journal:  Med Sci Monit       Date:  2001 Jul-Aug

2.  Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury.

Authors:  A Nakajima; K Wada; H Miki; N Kubota; N Nakajima; Y Terauchi; S Ohnishi; L J Saubermann; T Kadowaki; R S Blumberg; R Nagai; N Matsuhashi
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

3.  In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

Authors:  T L Yue Tl; J Chen; W Bao; P K Narayanan; A Bril; W Jiang; P G Lysko; J L Gu; R Boyce; D M Zimmerman; T K Hart; R E Buckingham; E H Ohlstein
Journal:  Circulation       Date:  2001-11-20       Impact factor: 29.690

4.  Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride.

Authors:  Kazuyoshi Kon; Kenichi Ikejima; Miyoko Hirose; Mutsuko Yoshikawa; Nobuyuki Enomoto; Tsuneo Kitamura; Yoshiyuki Takei; Nobuhiro Sato
Journal:  Biochem Biophys Res Commun       Date:  2002-02-15       Impact factor: 3.575

5.  Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.

Authors:  H Takano; T Nagai; M Asakawa; T Toyozaki; T Oka; I Komuro; T Saito; Y Masuda
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

Review 6.  Peroxisome proliferator-activated receptors in the cardiovascular system.

Authors:  D Bishop-Bailey
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

7.  Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes.

Authors:  K Yamamoto; R Ohki; R T Lee; U Ikeda; K Shimada
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

8.  The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation.

Authors:  Salvatore Cuzzocrea; Nicole S Wayman; Emanuela Mazzon; Laura Dugo; Rosanna Di Paola; Ivana Serraino; Domenico Britti; Prabal K Chatterjee; Achille P Caputi; Christoph Thiemermann
Journal:  Mol Pharmacol       Date:  2002-05       Impact factor: 4.436

9.  Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.

Authors:  Nassirah Khandoudi; Philippe Delerive; Isabelle Berrebi-Bertrand; Robin E Buckingham; Bart Staels; Antoine Bril
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

10.  Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction.

Authors:  Stefan Frantz; Kai Hu; Julian Widder; Barbara Bayer; Catharina Clara Witzel; Isabel Schmidt; Paolo Galuppo; Jörg Strotmann; Georg Ertl; Johann Bauersachs
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739
View more
  1 in total

Review 1.  Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies.

Authors:  George Robinson; Ines Pineda-Torra; Coziana Ciurtin; Elizabeth C Jury
Journal:  J Clin Invest       Date:  2022-01-18       Impact factor: 14.808
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.